Glanzmann's thrombasthenia (GT) is a rare congenital bleeding disorder associated with decreased platelet aggregation due to qualitative/quantitative deficiencies of the fibrinogen receptor. Severe bleeding episodes and perioperative bleeding are typically managed with platelet transfusions, although patients can develop anti-platelet antibodies or experience clinical refractoriness. The GT Registry (GTR) was established to collect efficacy/safety data on hemostatic treatments for GT, including recombinant factor VIIa (rFVIIa). At the request of the United States Food and Drug Administration, three hematology experts evaluated platelet refractoriness, antibody status, and rFVIIa efficacy data on a case-by-case basis to support a potential indication for rFVIIa in GT. Adjudication included 195 patients with 810 events (619 severe bleeding episodes, 192 surgeries), and a consensus algorithm was developed to describe adjudicators' coding of refractoriness and antibody status based on treatment patterns over time. Most rFVIIa-treated events were in patients without refractoriness or antibodies. Adjudicators rated most rFVIIa-treated bleeding episodes as successful (251/266, 94.4%; rFVIIa only, 101/109, 92.7%; rFVIIa 6 platelets 6 other agents, 150/ 157, 95.5%); efficacy was consistent in patients with platelet refractoriness 6 antibodies (75/79, 94.9%), antibodies only (10/10, 100.0%), and neither/unknown (166/177, 93.8%). Adjudicators also rated most rFVIIa-treated surgeries as successful (159/160, 99.4%; rFVIIa only, 65/66, 98.5%; rFVIIa 6 platelets 6 other agents, 94/94, 100.0%); efficacy was consistent in patients with platelet refractoriness 6 antibodies (69/70, 98.6%), antibodies only (24/24, 100.0%), and neither/unknown (66/66, 100.0%). Unblinding the adjudicators to investigator efficacy ratings changed few assessments. Doses of rFVIIa were narrowly distributed, regardless of other hemostatic agents used.
lowing repeated platelet transfusions, patients with GT may develop alloantibodies targeting GPIIb/IIIa or human lymphocyte antigen (HLA), and may experience clinical refractoriness to subsequent platelet treatment. [2] [3] [4] An additional therapeutic option for managing severe bleeding in patients with GT is recombinant factor VIIa (rFVIIa), which has been used successfully to control bleeding episodes and peri-operative bleeding in patients with GT, often in combination with antifibrinolytic therapy. [6] [7] [8] The precise mechanism by which rFVIIa promotes hemostasis is unknown, but is thought to include an increased activation of platelets, increased generation of thrombin, and increased deposition of fibrin, resulting in a stable and effective clot. [9] [10] [11] Because of the rarity of GT and difficulties in enrolling sufficient numbers of patients for a randomized controlled trial, a prospective multinational GT Registry (GTR) was established to collect data regarding the efficacy and safety of hemostatic treatments for GT, including rFVIIa. The registry was initiated as a postmarketing surveillance commitment to the European Union's Committee for Medicinal Products for Human Use, following approval by the European Medicines Agency of rFVIIa for the treatment of GT. 12 An external expert group monitored the registry and provided ongoing support of recruitment and analysis, including publication of primary data on the efficacy and safety of rFVIIa associated with specific patient events (bleeding episodes and surgeries). 13, 14 Investigators found rFVIIa used alone to be effective in a majority of bleeding episodes (111 of 122; 91.0%) and surgical procedures (59 of 62; 95.2%).
Following discussion with the United States Food and Drug Administration (FDA) regarding a potential new indication of GT for rFVIIa, an objective adjudication committee of US hematologists unaffiliated with the registry was assembled to evaluate rFVIIa efficacy, platelet refractoriness, and anti-platelet antibody (anti-GPIIb/IIIa and anti-HLA) data from the GTR. Patient data were reviewed independently by the three adjudicators on a case-by-case basis in the context of all available information, including data from multiple events that occurred in each specific patient. Here we present a detailed methodology of the adjudication process and results. These data were used to support the FDA approval in July 2014 of rFVIIa for patients with GT with refractoriness to platelet transfusions, with or without antibodies to platelets. 15 
| M E T H O D S

| Study population
A detailed description of the GTR data collection process has been presented elsewhere. 13, 14 Briefly, the registry was a prospective, observational, multinational, Web-based platform that collected safety and efficacy data regarding the use of systemic hemostatic treatments in patients with GT (see Supporting Information appendix for a list of data fields). Patients were eligible for participation in the GTR if they had a diagnosis of congenital GT and exhibited a normal platelet count and morphology. 13, 14 
| Statistical analysis
| R E S U LTS
The GTR contained data collected from 218 patients with GT who 
| Adjudicated rFVIIa efficacy
The mean (median) age of the rFVIIa-treated population at first recorded event was 24.2 (21.5) years. Whereas the majority of rFVIIatreated bleeding episodes occurred in patients aged 0 to 16 years (65%), most rFVIIa-treated surgical procedures occurred in patients older than 16 years (86%). A majority of patients were female (57%), and most were Caucasian (54%). The most common disease type was Type 1 (47%); 10% were Type II, 2% were Type III, and 41% were unknown.
| Bleeding episodes
The most frequently reported bleeding locations were epistaxis (44%), gum bleeding (18%), menorrhagia (14%), and oral bleeding associated with tooth or dental extraction (11%). None/unknown ---17 (100.0) 17 a Refers to antibody status specified and refractory none or unknown.
Shaded boxes reflect identical investigator and adjudicator ratings.
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AJH AJH Figure S2C ). These dosing data served as the basis for the indicated dosing for GT in the United States.
Overall, adjudicators rated most rFVIIa-treated bleeding episodes as successful (94.4%); few episodes were reported as a treatment failure (1.5%) ( Table 2 ). Rates of treatment success were similar between bleeding episodes treated with rFVIIa only (92.7%) and those treated with rFVIIa 1 other hemostatic agents (95.5%), and were similar between all adjudicator-assessed antibody/refractoriness categories (93.8% to 100.0%). Detailed information regarding dosing and efficacy by type of bleeding episode is shown in Supporting Information Table S1 .
| Surgical procedures
A majority of the surgical procedures were reported as elective (92%); 4% were reported as emergencies and 4% were unspecified. The most frequent types of surgical procedures were dental (66%), endoscopy Overall, adjudicators rated most rFVIIa-treated surgical procedures as successful (99.4%) ( Table 3 ). Rates of treatment success were similar between bleeding episodes treated with rFVIIa only (98.5%) and those treated with rFVIIa 1 other hemostatic agents (100.0%), and were similar between all adjudicator-assessed antibody/refractoriness categories (98.6% to 100.0%). Detailed information regarding dosing and efficacy by type of surgical procedure is shown in Supporting Information Table S1 .
| Investigator-reported vs. adjudicator-assessed effectiveness
Blinded adjudicator assessments of efficacy were largely consistent with investigator effectiveness ratings (Supporting Information Table   S2 ). Of the 255 bleeding episodes and 155 surgical procedures that were rated by investigators as effective or partially effective, 240 bleeding episodes (94.1%) and 154 surgeries (99.4%) were rated by the adjudicators as successful. Twelve bleeding episodes and one surgical procedure that were rated by the investigators as effective or partially effective were classified by the adjudicators as insufficient data. Of the five bleeding episodes and three surgical procedures that were rated by the investigators as ineffective, four bleeding episodes (80.0%) and three surgical procedures (100.0%) were classified by the adjudicators as successful; all eight of these events were in cases where rFVIIa was used in conjunction with other hemostatic agents and/or platelets.
The unblinding of adjudicators to investigator effectiveness ratings had minimal effect on adjudicator assessments. Seven bleeding episodes that were rated as insufficient data in adjudicators' blinded assessments were reclassified after un-blinding; one episode was reclassified to treatment success, one bleeding episode was reclassified to treatment failure, and five episodes were reclassified with no consensus. No surgical procedures were reclassified following unblinded review.
| DISCUSSION
Expert adjudication of the GTR data provided an objective assessment of individual patient case reports and a consistent approach towards determining platelet refractoriness, antibody status, and treatment
effectiveness. An important goal of the adjudication process was to reduce biases caused by variability in investigator assessments and incompleteness of data; adjudicators benefitted from an objective perspective in which patient data could be reviewed in the context of any additional events included in the registry, and assessments were based on patterns of treatment over time. These methods provide a unique way to examine observational data beyond descriptive statistics to learn more about the underlying disease state and treatment variability, and may provide a model for independent review of similar data sets.
The GTR is the largest observational study on GT and few previous studies have investigated rFVIIa efficacy data in this patient population, although the adjudicated rFVIIa efficacy findings are consistent with reports from these previous studies. Safety data from the GTR have been previously reported, and indicate a favorable safety profile of rFVIIa in patients with GT. 13, 14, 16 The only serious adverse event probably or possibly related to rFVIIa was a deep vein thrombosis reported in a 25-year-old female receiving rFVIIa, platelets, and packed red blood cells eight days after an emergency laparotomy for an ovarian cyst with hematoma and ureteral compression. Unlike previous published reports, the current analysis excluded events characterized by subcutaneous/easy bruising and those treated only with antifibrinolytics, which were considered to not meet criteria agreed upon for severe bleeds requiring systemic hemostatic therapy.
Prior publications are also based on an independent analysis of raw data files, and reflect collapsing of linked admissions to index events, exclusion of nonbleeding events, and recategorization of two bleeding episodes as surgical events (see figure 1 in Di Minno et al.
13
). While the multiple records for single admissions were easily identified based upon the "notes" provided in the CRFs reviewed and questioned by the adjudicators, the adjudication plan did not allow for consolidation of multiple records where each had an investigator-reported efficacy assessment; in contrast, the GTR External Expert Panel was able to consolidate those records with a single efficacy assessment.
An important limitation of the adjudication analysis presented here is the limited and variable amount of patient data provided by the investigators. The underlying raw data from EMA reporting was analyzed by the adjudicators, however, because the GTR had closed at the time of the analysis, adjudicators were limited to data and case narratives that had been submitted by the investigators, and had no opportunities to query the data. Additionally, although data on platelet refractoriness and antibody status could be reported by investigators during each event, these fields were not required in the registry. Adjudicators were also directed not to merge or consolidate treatment events, even if the case report forms clearly indicated that subsequent events had resulted from a single bleed, which contributed to some of the "insufficient data" or "no consen- 
